Idecabtagene vicleucel (ide-cel) vs standard regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KarMMa-3 analysis in high-risk subgroups Meeting Abstract
| Authors: | Raab, M. S.; Patel, K.; Rodríguez-Otero, P.; Manier, S.; Baz, R.; Cavo, M.; Callander, N.; Costa, L. J.; Moreau, P.; Solomon, S. R.; Chen, C.; Raje, N.; Scheid, C.; Delforge, M.; Larsen, J.; Pabst, T.; Suzuki, K.; Truppel-Hartmann, A.; Piasecki, J.; Felten, J.; Caia, A.; Cook, M.; Giralt, S.; Mateos, M. V. |
| Abstract Title: | Idecabtagene vicleucel (ide-cel) vs standard regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KarMMa-3 analysis in high-risk subgroups |
| Meeting Title: | 36. Deutscher Krebskongress - Fortschritt gemeinsam gestalten |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 47 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Feb 21-24 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2024-02-01 |
| Start Page: | 144 |
| Language: | English |
| ACCESSION: | WOS:001332646400339 |
| PROVIDER: | wos |
| DOI: | 10.1159/000535363 |
| Notes: | Meeting Abstract: 334 -- 'The 36th German Cancer Congress - Building Progress Together' -- Located in the section 'Novel Therapeutics: Targeted Therapies, Immunotherapies, Cellular Therapies' -- Source: Wos |
